-
Represented Zomedica Corp. (NYSE: ZOM), veterinary health company, in a $200 million underwritten offering of common shares.
-
Represented Reviva Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing therapies that address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases, in connection with a definitive agreement and plan of merger for a business combination with Tenzing Acquisition Corp. (NASDAQ: TZAC), a special purpose acquisition (SPAC), resulting in a total post-money equity value of the combined company of approximately $119 million.
-
Represented Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, in connection with an At-the-Market-Offering of shares of common stock for up to $150 million.
-
Represented Celldex Therapeutics, Inc. (NASDAQ: CLDX), a biopharmaceutical company focused on the development and commercialization of immunotherapies and other targeted biologics, in connection with a $130.4 million public offering of common stock.
-
Represented Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) in connection with its business combination with F-star Therapeutics Limited, in which Spring Bank acquired all of the outstanding share capital of F-star in exchange for newly issued shares of Spring Bank in a share exchange conducted under English law.
-
Represented Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, in connection with a $110 million underwritten public offering of common stock.
-
Represented Timber Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, in connection with its definitive merger with BioPharmX Corporation. Under the terms of the merger agreement, Timber Pharmaceuticals LLC merged into a wholly owned subsidiary of BioPharmX, with Timber surviving as a wholly owned subsidiary of BioPharmX.
-
Represented Voltron Therapeutics in connection with a joint venture with Hoth Therapeutics (NASDAQ: HOTH) to develop a Self-Assembling Vaccine (SAV) for COVID-19 with technology exclusively licensed by Voltron from the Vaccine and Immunotherapy Center at Massachusetts General Hospital. The joint entity will be called HaloVax.
-
Represented Artegraft, Inc., a processor and seller biologic vascular grafts derived from bovine carotid arteries and implanted primarily in hemodialysis access patients, in connection with the $90 million sale of its business and assets to LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of devices, implants and services for the treatment of peripheral vascular disease.
-
Represented Timber Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, in connection with a $25 million private placement of common stock and warrants.
-
Represented Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, in a $22 million underwritten public offering of shares and warrants and subsequent uplisting to the Nasdaq Capital Market.
-
Represented Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions, in connection with an At-the-Market offering with an aggregate offering price of up to $50 million.
-
Represented Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, in connection with an at-the-market offering of common stock of up to $75 million.
-
Represented Zomedica Pharmaceuticals Corp. (NYSE: ZOM), a veterinary diagnostic and pharmaceutical company, in a $20 million public offering of common stock and warrants.
-
Represented H.C. Wainwright & Co. as the sole book-running manager in connection with the $31.6 million underwritten public offering of common stock of Actinium Pharmaceuticals, Inc. (NYSE: ATNM), a clinical-stage biopharmaceutical company developing Antibody Radiation-Conjugates.
-
Represented Tonix Pharmaceuticals Holding Corp. (NASDQ: TNXP), a clinical-stage biopharmaceutical company focused on discovering and developing small molecules and biologics to treat pain, addiction and psychiatric conditions, in connection with an at the market offering of up to $50 million.
-
Represented Sonnet BioTherapeutics, Inc., a privately-held clinical stage biopharmaceutical company developing innovative targeted biologic drugs, in connection with its merger with Chanticleer Holdings, Inc. to form a company operating under the name Sonnet BioTherapeutics Holdings, Inc., with its shares trading on the Nasdaq Capital Market under the ticker symbol “SONN” and in connection with a private placement of $19 million and the acquisition of the global development rights for Atexakin Alfa from Relief Therapeutics SA.